MDT-AP-2120
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 18
- os_event
- true
- age_years
- 5
- sex
- M
- new_clusters
- C5
- umap1_2d
- 4.978788594
- umap2_2d
- 5.667597376
- umap1_3d
- 1.818219871
- umap2_3d
- 0.003825936
- umap3_3d
- -1.928493965
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.280
- HEDGEHOG_SIGNALING+0.220
- DNA_REPAIR+0.200
- COAGULATION+0.180
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.160
- XENOBIOTIC_METABOLISM+0.160
- KRAS_SIGNALING_DN+0.150
- ANGIOGENESIS+0.140
- ESTROGEN_RESPONSE_LATE+0.140
- SPERMATOGENESIS+0.140
Top 10 suppressed
- MYC_TARGETS_V2-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.320
- ANDROGEN_RESPONSE-0.310
- MITOTIC_SPINDLE-0.300
- TGF_BETA_SIGNALING-0.300
- UV_RESPONSE_DN-0.270
- INTERFERON_ALPHA_RESPONSE-0.230
- G2M_CHECKPOINT-0.210
- MYC_TARGETS_V1-0.210
- NOTCH_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2628 | Med | Medulloblastoma | 0.845 |
| 2 | MDT-AP-2389 | Med | Medulloblastoma | 0.809 |
| 3 | MDT-AP-2618 | Med | Medulloblastoma | 0.792 |
| 4 | MDT-AP-2619 | Med | Medulloblastoma | 0.782 |
| 5 | SRR1487321 | GTEX | — | 0.782 |
| 6 | TCGA-49-AAR0-01A-21R-A39D-07 | — | cohortA3 | 0.751 |
| 7 | MDT-AP-2573 | Med | Medulloblastoma | 0.746 |
| 8 | SRR1433431 | GTEX | — | 0.741 |
| 9 | SRR1381632 | GTEX | — | 0.733 |
| 10 | TCGA-LL-A5YL-01A-12R-A29R-07 | — | B | 0.732 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.090 | Idelalisib | — uncovered |
| COMPLEMENT | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.090 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.090 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| HYPOXIA | 0.060 | Idelalisib | — uncovered |
| MYOGENESIS | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.030 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.020 | Idelalisib | — uncovered |